What changed in Boston Scientific Corporation's latest annual report
In the year ended 31 Dec 2025, Boston Scientific Corporation's revenue rose 19.9% to USD 20.07bn, from USD 16.75bn; cash and cash equivalents rose 374.6% to USD 1.97bn, from USD 414.00m; shareholders' equity rose 11.3% to USD 24.23bn, from USD 21.77bn.
Year ended 31 Dec 2025. Source: 10-K filed 17 Feb 2026, read it on SEC EDGAR.
USD 16.75bn to USD 20.07bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 16.75bn | 20.07bn | Up 19.9% |
| Total assets | 39.40bn | 43.67bn | Up 10.9% |
| Cash and cash equivalents | 414.00m | 1.97bn | Up 374.6% |
| Shareholders' equity | 21.77bn | 24.23bn | Up 11.3% |
Questions people ask
Did Boston Scientific Corporation's revenue grow last year?
Revenue grew 19.9%, from USD 16.75bn to USD 20.07bn in the year ended 31 Dec 2025.
How much cash and debt does Boston Scientific Corporation have?
At its latest year end (31 Dec 2025), Boston Scientific Corporation reported cash and cash equivalents of USD 1.97bn.
Where do these numbers come from?
From Boston Scientific Corporation's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Boston Scientific Corporation?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%
- Solventum CorporationNet income up 224.8%